Switching on epigenetic therapy - PubMed

Switching on epigenetic therapy

Sascha Karberg. Cell. 2009.

Free article

Abstract

Reversible epigenetic changes that alter gene expression are a characteristic of many cancers and other diseases. Biotech companies are taking note and are starting to develop new drugs to reverse such pathogenic "epimutations."

Similar articles

• Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

  Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M. Sigalotti L, et al. J Cell Physiol. 2007 Aug;212(2):330-44. doi: 10.1002/jcp.21066. J Cell Physiol. 2007. PMID: 17458893 Review.

• Novel approaches on epigenetics.

  Papait R, Monti E, Bonapace IM. Papait R, et al. Curr Opin Drug Discov Devel. 2009 Mar;12(2):264-75. Curr Opin Drug Discov Devel. 2009. PMID: 19333872 Review.

• Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.

  Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM. Bishton M, et al. Expert Rev Anticancer Ther. 2007 Oct;7(10):1439-49. doi: 10.1586/14737140.7.10.1439. Expert Rev Anticancer Ther. 2007. PMID: 17944568 Review.

• Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells.

  Bar-Sela G, Jacobs KM, Gius D. Bar-Sela G, et al. Cancer J. 2007 Jan-Feb;13(1):65-9. doi: 10.1097/PPO.0b013e31803c7565. Cancer J. 2007. PMID: 17464248 Review.

• Histone deacetylation in epigenetics: an attractive target for anticancer therapy.

  Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R. Mai A, et al. Med Res Rev. 2005 May;25(3):261-309. doi: 10.1002/med.20024. Med Res Rev. 2005. PMID: 15717297 Review.

Cited by

• Biology of the Mi-2/NuRD Complex in SLAC (Stemness, Longevity/Ageing, and Cancer).

  Zhang Y. Zhang Y. Gene Regul Syst Bio. 2011 Feb 27;5:1-26. doi: 10.4137/GRSB.S6510. Gene Regul Syst Bio. 2011. PMID: 21523247 Free PMC article.

• Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

  Andreoli F, Barbosa AJ, Parenti MD, Del Rio A. Andreoli F, et al. Curr Pharm Des. 2013;19(4):578-613. doi: 10.2174/138161213804581918. Curr Pharm Des. 2013. PMID: 23016851 Free PMC article. Review.

• Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia.

  Xu B, On DM, Ma A, Parton T, Konze KD, Pattenden SG, Allison DF, Cai L, Rockowitz S, Liu S, Liu Y, Li F, Vedadi M, Frye SV, Garcia BA, Zheng D, Jin J, Wang GG. Xu B, et al. Blood. 2015 Jan 8;125(2):346-57. doi: 10.1182/blood-2014-06-581082. Epub 2014 Nov 13. Blood. 2015. PMID: 25395428 Free PMC article.

• Microbiome, inflammation, epigenetic alterations, and mental diseases.

  Alam R, Abdolmaleky HM, Zhou JR. Alam R, et al. Am J Med Genet B Neuropsychiatr Genet. 2017 Sep;174(6):651-660. doi: 10.1002/ajmg.b.32567. Epub 2017 Jul 10. Am J Med Genet B Neuropsychiatr Genet. 2017. PMID: 28691768 Free PMC article. Review.

• Accessing protein methyltransferase and demethylase enzymology using microfluidic capillary electrophoresis.

  Wigle TJ, Provencher LM, Norris JL, Jin J, Brown PJ, Frye SV, Janzen WP. Wigle TJ, et al. Chem Biol. 2010 Jul 30;17(7):695-704. doi: 10.1016/j.chembiol.2010.04.014. Chem Biol. 2010. PMID: 20659682 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database